Objective: To identify the efficacy of focal photocoagulation to maintain or achieve best corrected visual acuity (BCVA) ≥20/40 in eyes with clinically significant macular edema (CSME) that had a focal angiographic pattern.
Introduction
Diabetic retinopathy is a chronic and specific complication of diabetes mellitus, 1 and the leading cause of visual loss in working-aged population worldwide. 2, 3 A common cause of visual impairment in diabetic retinopathy is diabetic macular edema, which reduces the resolution power of the eye as a result of fluid accumulation in the macula, the region of the retina responsible for best corrected visual acuity (BCVA). 4 The fluid that thickens the macula may leak from microaneurisms or from dilated capillaries adjacent to zones without circulation; retinal fluorescein angiography reveals a focal pattern of leakage in the first case, and a diffuse pattern in the second. 4 Regardless of the angiographic pattern, the Early The risk of MVL is greater when the center of the macula is involved; the incidence of MVL is reduced by more than 50% for patients who undergo appropriate photocoagulation surgery, compared with those who are not treated. 6 Focal photocoagulation is the standard treatment for eyes with CSME with a focal angiographic pattern. 6 In the ETDRS vision improved for a minority of patients, and the goal of treatment with photocoagulation was to stabilize visual acuity; visual improvement after photocoagulation in the ETDRS occurred more frequently in patients with initial BCVA worse than 20/40, while those with initial vision ≥20/40 had less room to show an improvement; patients with CSME and excellent function should be considered for treatment before visual loss occurs. 6 The overall incidence of MVL in eyes treated with photocoagulation was 13% in a 3 year period, in the ETDRS; 7 recent studies have identified that over a third of the eyes with CSME treated with photocoagulation improve their BCVA.
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Although BCVA can improve after focal photocoagulation for CSME, the delay in the diagnosis may limit achieving a functional level that can provide visual independence. In a previous study from our population, 69% of patients with CSME had BCVA <20/40 at the moment of diagnosis; 12 consequently some patients may improve their vision or may not develop MVL, without reaching BCVA ≥20/40.
BCVA ≥20/40 is a functional level that provides visual independence, and that was used as a cutoff point in the ETDRS to identify patients with a higher probability of visual improvement; eyes with that functional level might also lose vision after photocoagulation, and may or may not preserve BCVA ≥20/40. Although visual improvement after photocoagulation is frequent in recent studies of CSME, the proportion of eyes that has BCVA ≥20/40 after treatment has not been identified recently.
A study was conducted to identify the efficacy of focal photocoagulation to maintain or achieve BCVA ≥20/40 in eyes with CSME who had a focal angiographic pattern.
Material and methods
A non-experimental, retrospective, longitudinal, descriptive study was conducted in diabetic patients with CSME of a general hospital in Mexico City, from October The files from patients treated with focal photocoagulation during the study period, who fulfilled the selection criteria were reviewed; CSME in all eyes was diagnosed by the same retina specialist, using The evolution of BCVA in each eye, and the incidence of moderate visual loss were identified in the sample and in each group. The study variable was the presence of BCVA ≥20/40 under subjective refraction, on the day of photocoagulation and 3 weeks after it.
The proportion and 95% confidence intervals (C.I.) of eyes with BCVA≥20/40 three weeks after treatment was identified, in the sample and within each group. Visual improvement was more common in group 1 than in group 2, a higher proportion of eyes in group 2 maintained BCVA than in group 1; these differences were statistically but not clinically significant ( achieved ≥20/40 BCVA.
Results

Age
Discussion
In the management of DME, laser surgery is a well proven treatment with very good efficacy; 13 the number needed to treat to prevent one case of moderate visual loss over 3 years is 8. 14 The ETDRS investigators had suggested that the reduced rate of moderate visual loss was mostly due to the effect of early focal photocoagulation, which should be considered for all eyes with CSME, as it leads to less chances of moderate visual loss, less loss of color vision, minor visual field changes and an increased chance of visual improvement; 15 the study found that this latter outcome was uncommon. 13 It is frequent to identify large changes in retinal thickness and BCVA in patients with greater retinal thickness before therapeutic interventions for CSME If BCVA <20/40 was considered visual loss before photocoagulation, the procedure would only be efficacious to revert it in 35% of the eyes; 71.9% of the eyes whose BCVA was ≥20/40 after photocoagulation had that vision rank before the procedure.
The proportion of eyes improving in the sample (43.5%) did not differ statistically from that of a previous study in our population (38.4%, p = 0.4), which also evaluated eyes with focal CSME; the proportion of eyes with BCVA <20/40 in that study (51.1%) did not either differ from that found in the present study (59.5%, p = 0.2) 10 Although the incidence of visual improvement was consistent, the proportion of eyes with BCVA ≥20/40 after focal photocoagulation had not been reported.
According to the results in the current study, up to 66.1% of the eyes with CSME could maintain or achieve BCVA ≥20/40; the proportion could vary according to the distribution of preoperative BCVA < 20/40, which emphasizes the need of a timely diagnosis, in order to offer the patient a better opportunity of having visual independence.
Conclusion
Focal photocoagulation in patients with CSME was efficacious to maintain BCVA ≥ 20/40 in 87.8% of eyes with that rank of vision preoperatively, and to achieve BCVA ≥20/40 in 35% of eyes with BCVA<20/40 before treatment.
